封面
市場調查報告書
商品編碼
1667945

二尖瓣疾病市場 - 全球產業規模、佔有率、趨勢、機會和預測,按治療類型、適應症、最終用戶、地區和競爭細分,2020-2030 年預測

Mitral Valve Disease Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Treatment Type, By Indication, By End-User, By Region & Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球二尖瓣疾病 (MVD) 市場價值為 32.5 億美元,預計將經歷顯著成長,2024 年至 2030 年的年複合成長率(CAGR) 為 8.85%。二尖瓣逆流(MR)和二尖瓣狹窄(MS)等疾病在世界各地普遍存在,為市場發展創造了巨大的機會。這一成長的主要促進因素包括人口老化、心血管疾病發病率不斷上升、醫療技術的不斷進步以及對微創治療方案的需求不斷增加。

市場概況
預測期 2026-2030
2024 年市場規模 32.5 億美元
2030 年市場規模 54.2 億美元
2025-2030 年複合年成長率 8.85%
成長最快的領域 修復段
最大的市場 北美洲

受診斷和治療創新以及對微創手術日益成長的偏好推動,該市場預計將經歷強勁成長。透過專注於改善患者治療效果、擴大醫療服務範圍和整合尖端技術,MVD 市場可望強勁擴張。隨著人們對二尖瓣疾病的認知不斷提高,特別是在老年人口中,對​​有效且可獲得的治療方案的需求也在增加,進一步促進了市場的成長。

主要市場促進因素

二尖瓣疾病 (MVD) 盛行率不斷上升

主要市場挑戰

治療費用高昂

主要市場趨勢

微創手術的興起

目錄

第 1 章:產品概述

第 2 章:研究方法

第 3 章:執行摘要

第 4 章:顧客之聲

第 5 章:二尖瓣疾病市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療類型(修復、置換、心臟再同步治療、治療學)
    • 依適應症(狹窄、脫垂、逆流)
    • 按最終使用者(醫院、門診手術中心、其他)
    • 按地區
    • 按公司分類(2024)
  • 市場地圖

第 6 章:北美二尖瓣疾病市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美:國家分析
    • 加拿大
    • 墨西哥

第 7 章:歐洲二尖瓣疾病市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲:國家分析
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章:亞太二尖瓣疾病市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區:國家分析
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章:南美洲二尖瓣疾病市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲:國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章:中東和非洲二尖瓣疾病市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA:國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章:市場動態

  • 驅動程式
  • 挑戰

第 12 章:市場趨勢與發展

  • 最新動態
  • 產品發布
  • 合併與收購

第 13 章:全球二尖瓣疾病市場:SWOT 分析

第 14 章:波特五力分析

第 15 章:競爭格局

  • Corcym UK Limited
  • Abbott Laboratories Inc
  • Zydus Lifesciences Limited
  • Medtronic plc
  • Edwards Lifesciences Corporation
  • Affluent Medical SA
  • ShockWave Medical, Inc.
  • Valcare Medical
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd.

第 16 章:策略建議

第17章 關於出版商,免責事項

簡介目錄
Product Code: 17684

The global Mitral Valve Disease (MVD) market was valued at USD 3.25 billion in 2024 and is projected to experience significant growth, with a compound annual growth rate (CAGR) of 8.85% from 2024 to 2030. The MVD market is rapidly expanding within the broader cardiovascular devices and treatments sector. Conditions like mitral valve regurgitation (MR) and mitral valve stenosis (MS) are prevalent worldwide, creating substantial opportunities for market development. Key drivers of this growth include an aging population, the increasing prevalence of cardiovascular diseases, continuous advancements in medical technologies, and rising demand for minimally invasive treatment options.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 3.25 Billion
Market Size 2030USD 5.42 Billion
CAGR 2025-20308.85%
Fastest Growing SegmentRepair Segment
Largest MarketNorth America

This market is expected to experience strong growth, fueled by innovations in diagnostics and treatments, alongside a growing preference for minimally invasive procedures. With a focus on improving patient outcomes, expanding access to care, and integrating cutting-edge technologies, the MVD market is poised for robust expansion. As awareness of mitral valve disease increases, particularly in aging populations, the demand for effective and accessible treatment options is also on the rise, further contributing to market growth.

Key Market Drivers

Growing Prevalence of Mitral Valve Disease (MVD)

The rising prevalence of mitral valve disease (MVD) is a primary factor driving the growth of the global MVD market. As MVD becomes more common worldwide, the demand for diagnostic services, treatment options, and healthcare infrastructure tailored to this condition is escalating. Alongside aging, modern lifestyle factors such as obesity, hypertension, diabetes, and smoking are contributing to the higher incidence of MVD. These lifestyle-related conditions are increasingly prevalent, particularly in emerging economies, driving the number of MVD cases.

Obesity is a major global concern, with one in eight individuals living with obesity as of 2022. The prevalence of adult obesity has more than doubled since 1990, with over 890 million adults affected. Hypertension is also widespread, with 1.28 billion adults aged 30 to 79 suffering from the condition, particularly in low- and middle-income countries. This growing incidence of hypertension and obesity directly impacts the prevalence of MVD, placing additional demand on healthcare systems.

The global increase in life expectancy further contributes to the rising incidence of MVD. As people live longer, the likelihood of developing MVD increases, resulting in a larger patient population requiring long-term treatment and management. The global life expectancy is projected to rise from 73.6 years in 2022 to 78.1 years by 2050, which presents both challenges and opportunities for healthcare businesses in addressing the needs of an aging population.

Additionally, as cardiovascular diseases (CVDs) continue to be the leading cause of global mortality, MVD is emerging as a significant contributor to heart failure and related complications. This escalating burden highlights the urgent need for effective diagnostic, treatment, and management solutions for MVD, thus driving market demand.

Key Market Challenges

High Treatment Costs

A major challenge for the growth of the Global Mitral Valve Disease Market is the high cost associated with diagnosis and treatment. Mitral valve diseases often necessitate complex surgical interventions or the implantation of prosthetic valves, which can be prohibitively expensive. Traditional open-heart surgeries and minimally invasive techniques such as transcatheter mitral valve repair (TMVR) both incur significant costs, including surgeon fees, operating room charges, and the cost of prosthetic devices.

Post-operative care and recovery for MVD patients also contribute to high healthcare costs, which include follow-up appointments, medications, and cardiac rehabilitation. In certain regions, inadequate insurance coverage for MVD treatments further compounds the financial burden, potentially deterring patients from seeking timely medical attention and hindering market growth.

Key Market Trends

Rise of Minimally Invasive Procedures

One of the prominent trends in the Global Mitral Valve Disease Market is the increasing adoption of minimally invasive procedures for diagnosing and treating MVD. Traditional open-heart surgery has long been the standard approach, but advances in medical technology have introduced less invasive options, such as transcatheter mitral valve repair (TMVR) and transcatheter mitral valve replacement (TMVR).

Minimally invasive procedures offer several advantages, including smaller incisions, reduced pain, shorter hospital stays, and faster recovery times. These benefits are driving greater patient demand for minimally invasive options, particularly among high-risk or elderly patients who may not be candidates for open-heart surgery. As healthcare professionals gain expertise in performing these procedures, their adoption is expected to continue to rise.

Key Market Players

  • Corcym UK Limited
  • Abbott Laboratories Inc.
  • Zydus Lifesciences Limited
  • Medtronic plc
  • Edwards Lifesciences Corporation
  • Affluent Medical SA
  • ShockWave Medical, Inc.
  • Valcare Medical
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

Report Scope:

This report segments the Global Mitral Valve Disease Market into the following categories, along with the industry trends:

Mitral Valve Disease Market by Treatment Type:

  • Repair
  • Replacement
  • Cardiac Resynchronization Therapy
  • Therapeutics

Mitral Valve Disease Market by Indication:

  • Stenosis
  • Prolapse
  • Regurgitation

Mitral Valve Disease Market by End-User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Mitral Valve Disease Market by Region:

  • North America: United States, Canada, Mexico
  • Europe: France, United Kingdom, Italy, Germany, Spain
  • Asia-Pacific: China, India, Japan, Australia, South Korea
  • South America: Brazil, Argentina, Colombia
  • Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape

This section provides a detailed analysis of major companies in the Global Mitral Valve Disease Market.

Available Customizations:

TechSci Research offers tailored customizations to the Global Mitral Valve Disease market report, providing specific data and insights according to a company's needs. Customization options include:

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Mitral Valve Disease Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Repair, Replacement, Cardiac Resynchronization Therapy, Therapeutics)
    • 5.2.2. By Indication (Stenosis, Prolapse, Regurgitation)
    • 5.2.3. By End-User (Hospitals, Ambulatory Surgical Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Mitral Valve Disease Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Indication
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Mitral Valve Disease Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Mitral Valve Disease Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Mitral Valve Disease Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By End-User

7. Europe Mitral Valve Disease Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By Indication
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Mitral Valve Disease Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By End-User
    • 7.3.2. United Kingdom Mitral Valve Disease Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By End-User
    • 7.3.3. Italy Mitral Valve Disease Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By End-User
    • 7.3.4. France Mitral Valve Disease Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Mitral Valve Disease Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By End-User

8. Asia-Pacific Mitral Valve Disease Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Indication
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Mitral Valve Disease Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By End-User
    • 8.3.2. India Mitral Valve Disease Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan Mitral Valve Disease Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea Mitral Valve Disease Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia Mitral Valve Disease Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By End-User

9. South America Mitral Valve Disease Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Indication
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Mitral Valve Disease Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By End-User
    • 9.3.2. Argentina Mitral Valve Disease Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By End-User
    • 9.3.3. Colombia Mitral Valve Disease Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By End-User

10. Middle East and Africa Mitral Valve Disease Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Indication
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Mitral Valve Disease Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By End-User
    • 10.3.2. Saudi Arabia Mitral Valve Disease Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By End-User
    • 10.3.3. UAE Mitral Valve Disease Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Mitral Valve Disease Market: SWOT Analysis

14. Porter's Five Forces Analysis

15. Competitive Landscape

  • 15.1. Corcym UK Limited
    • 15.1.1. Business Overview
    • 15.1.2. Product & Service Offerings
    • 15.1.3. Recent Developments
    • 15.1.4. Financials (If Listed)
    • 15.1.5. Key Personnel
    • 15.1.6. SWOT Analysis
  • 15.2. Abbott Laboratories Inc
  • 15.3. Zydus Lifesciences Limited
  • 15.4. Medtronic plc
  • 15.5. Edwards Lifesciences Corporation
  • 15.6. Affluent Medical SA
  • 15.7. ShockWave Medical, Inc.
  • 15.8. Valcare Medical
  • 15.9. Pfizer Inc
  • 15.10.Teva Pharmaceutical Industries Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer